<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742117</url>
  </required_header>
  <id_info>
    <org_study_id>11-006837</org_study_id>
    <secondary_id>5U01HL128606</secondary_id>
    <secondary_id>3U01HL128606-03S1</secondary_id>
    <nct_id>NCT01742117</nct_id>
  </id_info>
  <brief_title>Tailored Antiplatelet Therapy Following PCI</brief_title>
  <acronym>TAILOR-PCI</acronym>
  <official_title>Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spartan Bioscience Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Applied Health Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration
      (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary
      stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some
      studies have suggested that patients who have a certain genetic liver enzyme abnormality
      (known as cytochrome P450 2C19 [CYP2C19] *2 or *3 allele) may have a reduced ability to
      activate clopidogrel, and therefore may have a lowered response to clopidogrel. It is thought
      that perhaps people who have a coronary stent procedure may have this genetic liver enzyme
      abnormality. There is a research genetic test available to determine whether or not someone
      has this genetic liver enzyme abnormality. Ticagrelor, is a newer anti-platelet drug that is
      not dependent on the CYP2C19 liver enzyme for its activation and hence in poor clopidogrel
      metabolizers, alternative drugs like Ticagrelor have been recommended for use as an
      anti-platelet agent after PCI. The purpose of this study is to determine if genetic testing
      can identify the best anti-platelet therapy, for patients who undergo a coronary stent
      placement and do not activate clopidogrel very well.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAILOR-PCI is a multi-site, open label, prospective, randomized trial testing the hypothesis
      that after percutaneous coronary intervention (PCI), using a genotyping strategy ticagrelor
      90 mg twice per day is superior to clopidogrel 75 mg per day in reducing a composite endpoint
      of major adverse cardiovascular events (MACE), i.e., non-fatal myocardial infarction,
      non-fatal stroke, severe recurrent ischemia, cardiovascular (CV) death, and stent thrombosis
      (primary endpoints) in CYP2C19 reduced function allele patients. Patients who undergo PCI
      will be randomized to a conventional therapy arm (i.e., to receive clopidogrel 75 mg once
      daily without prospective genotyping guidance) versus a prospective CYP2C19 genotype-based
      anti-platelet therapy approach (ticagrelor 90 mg bid in CYP2C19 *2 or *3 reduced function
      allele patients, clopidogrel 75 mg once daily in non-*2 or -*3 CYP2C19 patients). Buccal
      swabs will be obtained for those subjects randomized to the prospective genotyping arm. All
      subjects will have a blood sample drawn for DNA analysis but genotyping using these DNA
      samples will be performed only after completion of the duration of anti-platelet therapy
      (i.e., after one year). The primary endpoints will be assessed prospectively and will be
      compared between the conventional arm and the prospective genotyping arm among those
      identified as reduced function CYP2C19 allele carriers according to the 1-year genotype
      results.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of the a major adverse cardiovascular event (MACE)</measure>
    <time_frame>Two years after percutaneous coronary intervention (PCI)</time_frame>
    <description>MACE will include non-fatal myocardial infarction, non-fatal stroke, cardiovascular mortality, severe recurrent ischemia, and stent thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with reduced function CYP2C19 allele(s) who have major or minor bleeding</measure>
    <time_frame>Two years after percutaneous coronary intervention (PCI)</time_frame>
    <description>Includes subjects who have bleeding events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">5300</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Stenosis</condition>
  <arm_group>
    <arm_group_label>Clopidogrel then Retrospective Genotyping</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 75 mg daily for 1 year after PCI. DNA samples at baseline to be frozen. At 12 months DNA will be genotyped to determine the *2 &amp; *3 reduced function/wild type allele status.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective Genotyping - Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with the wild type CYP2C19 allele (based on prospective genotype testing) will be assigned to receive a clopidogrel 75mg tablet daily for 1 year following PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective Genotyping - Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with the CYP2C19 heterozygous and homozygous *2 and *3 reduced function allele (based on prospective genotype testing) will be assigned to receive a ticagrelor 90 mg tablet twice per day for one year following PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Digital Sub-Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients previously enrolled in TAILOR-PCI in participating sites in U.S. and Canada will be invited to enroll in a digital sub-study through 24 months post PCI, utilizing their own smartphones.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Subjects will receive Clopidogrel, one 75 mg tablet per day by mouth for one year.</description>
    <arm_group_label>Clopidogrel then Retrospective Genotyping</arm_group_label>
    <arm_group_label>Prospective Genotyping - Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Subjects will receive Ticagrelor, one 90 mg tablet twice per day by mouth.</description>
    <arm_group_label>Prospective Genotyping - Ticagrelor</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Retrospective Genotype testing</intervention_name>
    <description>Mayo Clinic will use ABI TaqMan assay of three variants in the CYP2C10 gene: *2, *3 and *17</description>
    <arm_group_label>Clopidogrel then Retrospective Genotyping</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Prospective Genotype testing</intervention_name>
    <description>Rapid turnaround Spartan^TM Bioscience in vitro diagnostic assay for analysis of three variants in the CYP2C19 gene: *2, *3 and *17</description>
    <arm_group_label>Prospective Genotyping - Clopidogrel</arm_group_label>
    <arm_group_label>Prospective Genotyping - Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Smartphone</intervention_name>
    <description>Subjects will use their own iOS or Android smartphones to complete surveys and activities which will collect data on outcomes since their PCI, which can be compared to outcomes collected through study coordinator phone calls.</description>
    <arm_group_label>Digital Sub-Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  Patient &gt;18 years of age

          -  Patient presents with acute coronary syndrome (ACS) or stable coronary artery disease
             (CAD)

          -  Patient is eligible for PCI

          -  Patient is willing and able to provide informed written consent

        5.3 Exclusion

          -  Patient not able to receive 12 months of dual anti-platelet therapy

          -  Failure of index PCI

          -  Patient or physician refusal to enroll in the study

          -  Patient with known CYP2C19 genotype prior to randomization

          -  Planned revascularization of any vessel within 30 days post-index procedure and/or of
             the target vessel(s) within 12 months post-procedure

          -  Anticipated discontinuation of clopidogrel or ticagrelor within the 12 month follow up
             period, example for elective surgery

          -  Serum creatinine &gt;2.5 mg/dL within 7 days of index procedure

          -  Platelet count &lt;80,000 or &gt;700,000 cells/mm3, or white blood cell count &lt;3,000
             cells/mm3 if persistent (at least 2 abnormal values) within 7 days prior to index
             procedure.

          -  History of intracranial hemorrhage

          -  Known hypersensitivity to clopidogrel or ticagrelor or any of its components

          -  Patient is participating in an investigational drug or device clinical trial that has
             not reached its primary endpoint

          -  Patient previously enrolled in this study

          -  Patient is pregnant, lactating, or planning to become pregnant within 12 months

          -  Patient has received an organ transplant or is on a waiting list for an organ
             transplant

          -  Patient is receiving or scheduled to receive chemotherapy within 30 days before or
             after the procedure

          -  Patient is receiving immunosuppressive therapy or has known immunosuppressive or
             autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematous,
             etc.)

          -  Patient is receiving chronic oral anticoagulation therapy (i.e., vitamin K antagonist,
             direct thrombin inhibitor, Factor Xa inhibitor)

          -  Concomitant use of simvastatin/lovastatin &gt; 40 mg qd

          -  Concomitant use of potent CYP3A4 inhibitors (atazanavir, clarithromycin, indinavir,
             itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir,
             telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone,
             phenobarbital, phenytoin, rifampin, and rifapentine)

          -  Non-cardiac condition limiting life expectancy to less than one year, per physician
             judgment (e.g. cancer)

          -  Known history of severe hepatic impairment

          -  Patient has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions

          -  Patient has an active pathological bleeding, such as active gastrointestinal (GI)
             bleeding

          -  Inability to take aspirin at a dosage of 100 mg or less

          -  Current substance abuse (e.g., alcohol, cocaine, heroin, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naveen Pereira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael E Farkouh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kent R Bailey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp HealthCare</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuckerberg San Francisco General</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCH Heart Institute</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Healthcare</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essentia Institute of Rural Health</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Feinstein Institute for Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates of Schenectady</name>
      <address>
        <city>Schenectady</city>
        <state>New York</state>
        <zip>12309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHS, Eau Claire</name>
      <address>
        <city>Eau Claire</city>
        <state>Wisconsin</state>
        <zip>54702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Health System</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital, UBC Division of Cardiology</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5N 3W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Sciences Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humber River Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Services Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital - UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regina General Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchawan</state>
        <zip>S4P 0W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konyang University College of Medicine</name>
      <address>
        <city>Daejeon</city>
        <zip>302-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Especialidades, Centro Medico Nacional 'La Raza'</name>
      <address>
        <city>Mexico City</city>
        <zip>02990</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital REgional No. 1</name>
      <address>
        <city>Mexico City</city>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cardiologia, Centro Medico Nacional Siglo XXI</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Naveen L. Pereira</investigator_full_name>
    <investigator_title>Professor of Medicine, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

